Latest Neurology News

Argent BioPharma has completed its largest commercial shipment of CannEpil® to Ireland, marking a key milestone in its European expansion with a delivery valued at approximately AUD 783,000. The product is fully reimbursed under Ireland’s National Health Insurance scheme, enhancing patient access for refractory epilepsy treatment.

Invex Therapeutics reports a net loss of $715,582 for H1 2026 while advancing its Exenatide program targeting neurological diseases, alongside notable board reshuffles.

Actinogen Medical has received an additional $1.87 million R&D tax incentive rebate, bringing its total FY 2025 rebate to $7.36 million, while its Alzheimer’s phase 2b/3 trial progresses with promising safety results.

Neuren Pharmaceuticals has dosed the first patient in its groundbreaking Phase 3 trial of NNZ-2591 for Phelan-McDermid syndrome, a rare genetic disorder with no approved therapies. The trial marks a significant step forward for the PMS community and rare disease drug development.

The US Congress has reauthorized the Rare Pediatric Disease Priority Review Voucher program through September 2029, a move that could significantly benefit Neuren Pharmaceuticals as it advances its rare disease drug candidates.

Neuren Pharmaceuticals has received detailed feedback from the US FDA on its clinical development plans for NNZ-2591 targeting hypoxic ischemic encephalopathy and Pitt Hopkins syndrome, paving a clearer path forward despite some delays.

Micro-X has initiated installation of its first human pilot site for a portable Head CT scanner at Royal Melbourne Hospital, marking a pivotal step towards revolutionising stroke diagnosis with carbon nanotube technology.

Acadia Pharmaceuticals has received a negative vote from the European Medicines Agency’s committee on its application to market trofinetide for Rett syndrome in the EU, prompting plans for a re-examination request.

Neurotech International has secured ethics approval to launch its Beyond Harmony Phase 3 clinical trial of NTI164 for autism spectrum disorder, marking a key step toward regulatory submissions in Australia and the US.

Alterity Therapeutics has bolstered its Phase 2 data for ATH434 in Multiple System Atrophy and is advancing regulatory plans for a pivotal Phase 3 trial, supported by a robust cash position of A$49.2 million.

Neurotech International has secured a Rare Pediatric Disease Designation from the FDA for its lead drug NTI164 targeting Rett syndrome, alongside publishing promising clinical data and raising $8.7 million to fuel further development.

Argent BioPharma has restructured its acquisition of AusCann assets to sharpen its clinical focus and secured a substantial A$11 million financing facility, positioning itself for growth in 2026.